Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 6/20 | 0.43 |
| ▸ | TRPM4 | Q8TD43 | 4/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23088000 | 0.84 | SIRT1 (0.44) | TRPM5TRPM4AADAT | |
| SCHEMBL10467284 | 0.82 | FABP4 (0.49) | — | |
| SCHEMBL29673179 | 0.80 | KDM4C (0.46) | PTGDRPTGDR2 | |
| SCHEMBL28766567 | 0.80 | KDM4C (0.46) | PTGDRPTGDR2 | |
| SCHEMBL6582614 | 0.78 | MAPT (0.37) | ALDH1A1CASP1 | |
| SCHEMBL19926708 | 0.78 | ACHE (0.39) | PTGDR2ALDH1A1TSHR | |
| SCHEMBL27864837 | 0.77 | OPRK1 (0.46) | SRD5A1SRD5A2ALDH1A1TP53 | |
| SCHEMBL8118995 | 0.76 | HRH2 (0.48) | ALDH1A1 | |
| SCHEMBL23088507 | 0.76 | MEN1 (0.52) | TRPM5ALDH1A1TSHR | |
| SCHEMBL10818600 | 0.75 | ABAT (0.42) | TRPM5TRPM4AADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| EP-2203454-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. Organon (NL) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037220-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | TRPM5 1692/4885TRPM4 2012/4885CDC25B 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.